BACKGROUND: Efavirenz (EFV) causes neuropsychiatric side-effects and an unfavorable blood lipid profile. We investigated the effect of replacing EFV with @entity5197 (RAL) on @entity1 preference, @entity25 , @entity25 , @entity148 , and lipid levels. METHOD: Switch-ER was a randomized, double-blind, cross-over study. @entity1 who tolerated EFV, with less than 50 copies/ml @entity645 -RNA, were randomized into two groups: the RAL-first group started with RAL (400 mg twice daily) and EFV placebo, and the EFV-first group with EFV (600 mg once daily) and RAL placebo. After 2 weeks, both groups switched to the alternate regimen. The primary endpoint was @entity1 preference for the first or the second regimen, assessed after 4 weeks. RESULTS: Fifty seven @entity1 were enrolled with a median CD4 cell count 600/ l, and duration of previous EFV therapy 3.4 years. Fifty three @entity1 completed the study. When asked about treatment preference after 4 weeks, 22 preferred RAL and 12 preferred EFV, whereas 19 did not express a preference. A significant difference in @entity148 and stress scores favoring RAL (P = 0.04 and 0.03, respectively) was observed. Median plasma @entity165 levels decreased by 0.4 mmol/l (16 mg/dl, P < 0.001), @entity1674 by 0.2 mmol/l (18 mg/dl, P = 0.036), and low-density lipoprotein by 0.2 mmol/l (8 mg/dl, P = 0.004) after replacing EFV with RAL. After study completion, 51% of @entity1 switched to RAL. CONCLUSION: Half of @entity1 previously on a stable EFV preferred to switch to RAL, after double-blind exposure to RAL for 2 weeks. Substitution of EFV by RAL significantly impacted on lipid levels, stress, and @entity148 scores.

A randomized cross-over study to compare XXXX and efavirenz (SWITCH-ER study).

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'patient'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity645 :: ('57667', 'Species') :: ['HIV'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity5197 :: ('MESH:C507898', 'Chemical') :: ['raltegravir'] @entity25 :: ('MESH:D012893', 'Disease') :: ['daytime sleepiness', 'sleep quality'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity5197 :: (MESH:C507898,Chemical) :: ['raltegravir']
